Loading...
Loading...
Bank of America maintains its Buy rating on ViroPharma
VPHM and raises its target price to $32 from $23 on increased confidence reflecting three years of exclusivity through acquisition of Vancocin.
BofA writes, “In our view, this development positively impacts EPS, visibility on cash flow, balances risk between multiple products and preserves an upside scenario that was difficult to model previously. We estimate Vancocin over the next 3 years will generate $500M in cumulative cash (~20% of market cap, +$3/sh NPV).”
VPHM closed at $27.80 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in